I wonder if the click up last week was due to speculation on the latest Sarepta PO. Sarepta intends to use the net proceeds from the $325 million offering principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies. Just a thought. Full story here: https://www.streetinsider.com/Corporate+News/Sarepta+Therapeutics+%28SRPT%29+Prices+7.65M+Share+Common+Offering+at+%2442.50Sh/13124495.html
Interesting read. Reassuring that Glynn et al have got the right approach. http://www.fiercebiotech.com/biotech/fda-news-drugs-director-slams-sarepta-says-biotech-s-approval-not-a-good-model
Good interview with Jim Mellon re Brexit, the Italians and the rest of Europe. Gets interesting from about 14 mins till the end. http://www.lse.co.uk/SharePrice.asp?SharePrice=summ&goButton=Go
Pom, I'm not sure what you are going on about. I was the originator of the post. GP68 Then then started raving on about that it was meaningless and filtered me. His choice I suppose. My reply to him at 10:24 was have a lovely day. How's that getting upset. For the record I have not reported anyone's posts.
Price Target Analysis: According to the analysts, Summit Therapeutics plc (NASDAQ:SMMT) currently has a Mean Price Target of $28.67. The Low and High Price targets are $18 and $42, respectively. These price targets are a consensus analysis of 6 brokers.
Not sure I agree with this but here's the article none the less. http://www.thecountrycaller.com/27217-sarepta-therapeutics-inc-srpt-and-summit-therapeutics-dmd-deal-viewed-bullishly-analyst/
Hold on in there guy's. This is going to rocket. To day is the first time I have broke even in 6 years. Dont lose your nerve, dont top slice yet. Wait for it to play out. Can someone remind me when we are due to dose the last patient in our Phase Out DMD Trial as there is another $40 mio coming then as well. That's without our C-Diff Ridi deal.